BRIEF-Neuphoria Announces Initiation Of Strategic Review

Reuters11-11

Nov 11 (Reuters) - Neuphoria Therapeutics Inc NEUP.O:

NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUE
NEUPHORIA THERAPEUTICS: CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF INTEREST AND DIRECTOR NOMINATIONS FROM LYNX1 MASTER FUND LP
NEUPHORIA THERAPEUTICS INC - ON NOV 10, LYNX1 MASTER FUND OFFERS $5.20 PER SHARE IN CASH FOR NEUPHORIA

Source text: ID:nGNX7PmsfF

Further company coverage: NEUP.O

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582691113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582691113","market":"fut","top_or_hot":-1,"title":"BRIEF-Neuphoria Announces Initiation Of Strategic Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neuphoria Announces Initiation Of Strategic Review </title></head><body><p><span>Nov 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/NEUP\">Neuphoria Therapeutics Inc</a> <span>NEUP.O</span>:</p><ul><li><p>NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUE</p></li><li><p>NEUPHORIA THERAPEUTICS: CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF INTEREST AND DIRECTOR NOMINATIONS FROM LYNX1 MASTER FUND LP</p></li><li><p>NEUPHORIA THERAPEUTICS INC - ON NOV 10, LYNX1 MASTER FUND OFFERS $5.20 PER SHARE IN CASH FOR NEUPHORIA</p></li></ul><p>Source text: <span>ID:nGNX7PmsfF</span></p><p>Further company coverage: <span>NEUP.O</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neuphoria Announces Initiation Of Strategic Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neuphoria Announces Initiation Of Strategic Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neuphoria Announces Initiation Of Strategic Review </title></head><body><p><span>Nov 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/NEUP\">Neuphoria Therapeutics Inc</a> <span>NEUP.O</span>:</p><ul><li><p>NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUE</p></li><li><p>NEUPHORIA THERAPEUTICS: CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF INTEREST AND DIRECTOR NOMINATIONS FROM LYNX1 MASTER FUND LP</p></li><li><p>NEUPHORIA THERAPEUTICS INC - ON NOV 10, LYNX1 MASTER FUND OFFERS $5.20 PER SHARE IN CASH FOR NEUPHORIA</p></li></ul><p>Source text: <span>ID:nGNX7PmsfF</span></p><p>Further company coverage: <span>NEUP.O</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUA1Z01QK:1","article_id":"2582691113","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582691113","pubTimestamp":1762865746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neuphoria Announces Initiation Of Strategic Review Nov 11 (Reuters) - Neuphoria Therapeutics Inc NEUP.O:NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUENEUPHORIA ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NEUP":"Neuphoria Therapeutics Inc"},"translate_title":"简报-Neuphoria宣布启动战略审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEUP":0.9},"content_text":"BRIEF-Neuphoria Announces Initiation Of Strategic Review Nov 11 (Reuters) - Neuphoria Therapeutics Inc NEUP.O:NEUPHORIA ANNOUNCES INITIATION OF STRATEGIC REVIEW TO MAXIMIZE STOCKHOLDER VALUENEUPHORIA THERAPEUTICS: CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF INTEREST AND DIRECTOR NOMINATIONS FROM LYNX1 MASTER FUND LPNEUPHORIA THERAPEUTICS INC - ON NOV 10, LYNX1 MASTER FUND OFFERS $5.20 PER SHARE IN CASH FOR NEUPHORIASource text: ID:nGNX7PmsfFFurther company coverage: NEUP.O ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582691113","isCrawlerRequest":true}